Shareholders that Lost Money on Neurogene Inc. (NGNE) Should Contact Levi & Korsinsky About Securities Fraud Investigation - NGNE
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential securities fraud. This follows Neurogene's recent press release on interim clinical data from its NGN-401 gene therapy trial for Rett syndrome.
November 13, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Neurogene Inc. is under investigation by Levi & Korsinsky for potential securities fraud, following a press release on clinical data for its NGN-401 gene therapy trial.
The investigation into potential securities fraud could negatively impact investor confidence and the stock price of Neurogene Inc. The legal scrutiny follows the release of clinical data, which may have raised concerns about the company's disclosures.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100